spacer
home > pmps > winter 2003 > taking nasal drug delivery seriously: examples of pain-free and user-friendly alternative
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Taking Nasal Drug Delivery Seriously: Examples of Pain-Free and User-Friendly Alternative

Nasal Drug Delivery

Nasal sprays and drops have been used extensively for decades to prevent and treat ailments such as nasal congestion and allergic rhinitis. More recently the nasal route has been recognised as a convenient, reliable and non-invasive alternative to the parenteral route for the systemic administration of several compounds. Using this delivery route, nasal mucosa acts as a portal of entry for drugs into the bloodstream and potentially has a similar pharmaco-kinetic profile as drugs delivered intravenously. In particular, research has been exploring the direct transport of drugs from the nasal cavity to the central nervous system (CNS).

Drug development in the 21st century will not only rely on innovative new compounds and sophisticated formulations, but also on the efficiency, safety and comfort of the dispensing systems. The ideal 'nasal spray drug delivery device' should have optimum performance, (accurate and reproducible dose, narrow spray droplet size distribution; and support patient compliance, thus contributing to the reduction in global health expenditure. In addition, patients are now behaving more like consumers, and key issues such as device convenience, ease-of-use, attractiveness of the design and style, will reinforce brand recognition and loyalty, which will ultimately contribute to product success.

Nasal devices have progressively evolved from pipettes and droppers through to spraying devices such as squeeze bottles (which do not control the dose of drug delivered or the quality of the spray), towards metering spray pumps and valves and unit-dose nasal spray devices.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Pierre Carlotti, Marketing Director at Valois Pharmaceutical Division

Pierre Carlotti holds a Masters degree in Biology and a degree in Business Administration. Before taking the position of Marketing Director at Valois, he was Business Development Manager for a line of drug delivery devices. Before joining Valois, Pierre held various positions in sales, business development and marketing at West Pharmaceutical Services and Sanofi-Synthelabo.

spacer
Pierre Carlotti
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma Celebrates 15 Years of Growth and Success

Vilnius, Lithuania, July 16, 2019 ─ Northway Biotechpharma, a leading biopharmaceutical contract development and manufacturing organization (CDMO), celebrates its 15th anniversary today. As a midsized CDMO, Northway Biotechpharma is able to provide flexibility and responsiveness backed by a strong foundation in science and technology. The company focuses on understanding its customers and meeting their specific needs without binding them to one single approach. It is able to react rapidly to unexpected project changes, adjusting timelines, capacities and other activities to meet its customers’ evolving needs. On average, Northway Biotechpharma has 25–30 development projects underway each year, ranging from gene cloning to final drug product manufacturing.
More info >>

White Papers

Risk-Based Inspection Readiness: Reducing Headaches with Advanced Preparation

The Avoca Group

So often, inspections are a major source of stress in the clinical trial environment. This is especially true when processes involved in preparing for an inspection are reactive. But, it doesn’t have to be that way. Using industry-leading practices and resources enables a proactive approach to mitigate—or even eliminate—the pain points associated with preparing for inspections.
More info >>

 
Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement